Remembering Phil Lesh: A Life That Included Prostate and Bladder Cancer

Two cancers, decades apart

Phil Lesh, bassist and co-founder of the Grateful Dead, died on Friday, October 25, 2024, at 84. Rolling Stone reported the family's statement: he passed peacefully, surrounded by family. No cause of death was given, and we will not guess at one.

Rolling Stone also records the health history he made public. In 1998 he received a liver transplant for hepatitis C he had caught decades earlier. That turned him into a vocal organ-donor advocate. He survived prostate cancer in 2006. In 2015, the year of the band's Fare Thee Well shows, he disclosed that he had bladder cancer.

Two different cancers, nine years apart, in a man who kept playing. Those are separate diseases with almost nothing in common except the part of the body they sit near, and the pair is worth pulling apart.

Where each one starts

The prostate is a gland below the bladder, wrapped around the urethra, the tube that carries urine out. Prostate cancer starts in the gland's own cells.

The bladder is the hollow muscular bag that stores urine. Its inner surface is lined with urothelium. That stretchy lining runs the whole length of the urinary tract, from the kidney's collecting funnel down to the urethra. NCI reports that more than 90 percent of bladder cancers start in it. They are called transitional cell carcinomas, or urothelial carcinomas. About 2 to 7 percent are squamous cell carcinomas. About 2 percent are adenocarcinomas.

That lining detail explains an awkward feature of bladder cancer. Urothelial tumors are often multifocal, meaning more than one appears at once. So if a tumor is found, the whole lining has to be checked. NCI calls imaging of the upper urinary tract essential for staging and follow-up.

The symptom that matters most

For bladder cancer, one sign dominates. NCI states that bladder cancer typically presents with gross or microscopic hematuria — blood in the urine, either visible or picked up only on a dipstick test. Less often people report needing to pass urine frequently, getting up at night, or pain on passing urine.

Visible blood in the urine is common and usually benign. Infections and stones cause it far more often than cancer. The rule is not to panic. It is to get it looked at, once, properly, rather than assume it settled on its own.

If bladder cancer is suspected, NCI is clear that the most useful test is cystoscopy — a thin camera passed into the bladder. It also states plainly that CT scans and ultrasound are not sensitive enough to rule bladder cancer out. A normal scan is not an all-clear.

What treatment looks like

Bladder cancer splits at one line: has it reached the muscle wall?

Non-muscle-invasive tumors are removed through the urethra, usually followed by a dose of chemotherapy placed directly into the bladder. After that, NCI describes surveillance for low-risk tumors. Tumors at higher risk of progressing get at least a year of BCG. That stands for bacillus Calmette-Guérin, a live weakened bacterium that stirs up an immune response inside the bladder.

Muscle-invasive disease is different. Treatment aimed at cure is either cisplatin-based chemotherapy followed by removal of the bladder, or radiation given alongside chemotherapy.

Prostate cancer runs on a different logic. Many of those tumors grow slowly enough that treatment can do more harm than the cancer would. Our guide to prostate cancer screening explains why NCI says there is no standard or routine screening test. It also covers what the PSA blood test can and cannot settle.

When to get checked

• Blood in the urine, visible or found on a routine dipstick. Once is enough to warrant a look.
• A change in how you pass urine that lasts more than a few weeks: weaker stream, urgency, hesitancy, or getting up repeatedly at night.
• Pain on passing urine that antibiotics did not fix.
• A smoking history, current or past. NCI names tobacco, especially cigarettes, as a leading risk factor for bladder cancer. So is workplace exposure to dyes, paints, metals, and petroleum products.
• Age over 45 with any of the above, or a family history of either cancer, is a reason to start the screening conversation rather than wait.

What this does not mean

• No cause of death was announced for Phil Lesh. Nothing here should be read as one, and living with two earlier cancers does not imply either was involved.
• Surviving one cancer does not protect against another. Prostate and bladder cancers share risk factors like age and smoking, but they are unrelated diseases.
• SEER records five-year relative survival for bladder cancer at 79.1 percent overall, drawn from diagnoses made in the seven years 2016 through 2022. Half of all cases are found in situ, meaning still inside the lining layer, where the figure reaches 98.0 percent. Once the cancer has spread to distant sites, it is 9.6 percent. These are group averages from people diagnosed years ago. They describe populations, not people.
• Recurrence is a normal part of bladder cancer follow-up, not a sign that treatment failed. It is why cystoscopic surveillance continues for years.
• Nothing above is a substitute for having a urine sample tested when something changes.

Sources

• Rolling Stone: Phil Lesh, Grateful Dead co-founder and bassist, dead at 84
• NCI PDQ: Bladder Cancer Treatment (Health Professional Version)
• NCI PDQ: Prostate Cancer Screening (Patient Version)
• NCI SEER Cancer Stat Facts: Bladder Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.